All In Biotech

BLA 761263 · Genentech INC

Lunsumio Velo

Mosunetuzumab-Axgb · Injection

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

CDER novel approval, Dec 22, 2022: To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Dec 22, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

56

5 Phase 3, 29 recruiting

FAERS reports

1,107

950 serious, 156 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CYTOKINE RELEASE SYNDROME Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 and 2.4) and Warnings and Precautions (5.1) ] . WARNING: CYTOKINE RELEASE SYNDROME See full prescribing information for complete boxed warning. Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity. ( 2.1 , 2.4 , 5.1 )

What it is approved for

From the label in effect Jun 29, 2026.

LUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) 1.1 Follicular Lymphoma LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Mechanism: Mosunetuzumab-axgb is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and some healthy B-lineage cells. In vitro, mosunetuzumab-axgb activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2025 Supplement 6 · Efficacy OrphanLetterLabelMedication Guide
  • Nov 22, 2024 Supplement 5 · Efficacy OrphanLabelLetter
  • Dec 22, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
4 products under this application
  • LUNSUMIO VELO · MOSUNETUZUMAB-AXGB 5MG/0.5ML · INJECTABLE, INJECTION · Prescription
  • LUNSUMIO · MOSUNETUZUMAB-AXGB 1MG/ML · INJECTABLE, INJECTION · Prescription
  • LUNSUMIO VELO · MOSUNETUZUMAB-AXGB 45MG/ML · INJECTABLE, INJECTION · Prescription
  • LUNSUMIO · MOSUNETUZUMAB-AXGB 30MG/30ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mosunetuzumab" as an intervention, any sponsor and status, largest first.

All 56 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cytokine release syndrome299
  • disease progression134
  • neutropenia96
  • off label use77
  • pyrexia72
  • covid-1969
  • death52
  • pneumonia51
  • malignant neoplasm progression46
  • rash44
  • covid-19 pneumonia41
  • thrombocytopenia34

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20184
20195
202016
202152
202283
2023335
2024104
2025195
2026313

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lunsumio (Mosunetuzumab-Axgb)

2024 spending

$213K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$579.72 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$212,983

Part B: Lunsumio (Mosunetuzumab-Axgb) · HCPCS J9350

2024 spending

$25.6M

Beneficiaries

210

1,350 claims

Per beneficiary

$121,760

2024 ASP limit $632.86 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$11,542,465
2024$25,569,692

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Roche (Genentech) · Also marketed as Lunsumio

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.